Filing Flows › Allarity Therapeutics (ALLR) › Q1 2026
Allarity Therapeutics (ALLR) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
Allarity Therapeutics (ALLR) reported revenue of $25K for the first quarter 2026 (Q1 2026).
Allarity Therapeutics, Q1 2026: revenue $25K, net loss $2.8M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $25K | — | — |
| Operating profit | −$2.7M | — | — |
| Net earnings | −$2.8M | — | — |
| Operating cash flow | −$4.5M | — | — |
What changed
Revenue was $25K in Q1 2026.
Operating costs exceeded revenue by $2.7M, an operating margin of -10752.0%. The quarter ended with a net loss of $2.8M.
Operating cash flow was −$4.5M. Non-cash charges added back $160K of share-based compensation. Working capital and other items used $1.9M. Capital expenditures of $64K exceeded it, leaving free cash flow of −$4.6M.
Questions
What was Allarity Therapeutics' revenue in the first quarter 2026?
Allarity Therapeutics (ALLR) reported revenue of $25K for the first quarter 2026 (Q1 2026).